Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-828 vs Telmisartan + S-amlodipine in Healthy Volunteers
NCT02250833Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of telmisartan + levamlodipine in hypertension (HTN) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Quantifiable Concentration. Started Sep 2014; status: completed.
02
Drugs
telmisartan + levamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02250833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250833.